PeptideStack
5.2kquestions
20kanswers
220users

Is a 31G needle the right choice for drawing retatrutide at 20 mg/mL?

Asked 13 Mar 2026Modified 4 months agoViewed 13k times
24

Numbers first: a 31G needle · retatrutide · 20 mg/mL.

I want to know what the trade-off actually is rather than which option is fashionable.

I would rather have a defensible reason than a marginal improvement.

Which axes does this decision turn on?

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
shareeditfollowflag
FV
askedfill_volume22k3813 Mar 2026
Voting to keep this open — it is more specific than it first looks. – samir_bennani 4 months ago
add a comment

2 Answers

Sorted by votes
47

At 20 mg/mL a 1 mg dose is 0.05 mL — 5 units on a U-100 barrel — and no needle gauge changes that number. Gauge changes three other things: how long the draw takes, how much stays behind in the hub, and how much rubber you core out of the stopper. On the 31G scale a larger number is a finer needle, so a 31G needle is fine enough that a viscous solution draws slowly and a hurried draw pulls bubbles. If you are drawing 5 units at a time, the dead space matters more than the bore: a fixed-needle barrel loses microlitres, a luer hub loses tens of them, and at 20 mg/mL each microlitre is 20 µg.

The short version: 21G to 23G to draw, 29G to 31G to inject, and never the same needle for both.

For injecting, 29G to 31G is the usual range and the difference in perceived discomfort between them is small. Needle length matters more than gauge for comfort at these volumes.

The relevant detail is that a 30G or 31G needle through a butyl stopper leaves a track that reseals, which is why fine-gauge repeated entry is tolerable and coarse-gauge repeated entry is not.

Higher gauge is not automatically better; it is thinner, which has costs as well as benefits.

Length affects comfort more than gauge does at these volumes.

shareimprove this answerflag
SK
answereds_kalniete57k3811 Apr 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
32

More usefully, this is a straightforward answer that people over-complicate because the numbering is counter-intuitive.

Very fine needles are more prone to bending and to blocking with any particulate, which is a practical argument for inspecting the solution before drawing.

Typical outer diameters: 21G is about 0.82 mm, 23G about 0.64 mm, 25G about 0.51 mm, 29G about 0.34 mm and 31G about 0.26 mm. The gauge number and the diameter move in opposite directions.

The Hagen–Poiseuille relation gives flow proportional to the fourth power of radius, which is the quantitative basis for every gauge recommendation here.

If a solution will not draw through a 25G needle, the problem is the solution rather than the needle.

Flow goes as the fourth power of radius. That is why the difference feels so large.

shareimprove this answerflag
HP
answeredh_pergande71k15831 Mar 2026
6Thank you — the worked example is what makes this usable. – laminar_bench 4 months ago
7Thank you — this is the answer I was looking for. – rania_haddad 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.